Overcome Translational & Clinical Challenges to Develop Disease-Modifying Drugs for IPF, the Archetypal Fibrotic Disease. From Dissecting Mechanisms of Epithelial Dysfunction to Discovering Patient Reported Outcomes for More Meaningful Clinical Trials, Uncover Scientific Advancements & Actionable Insights to Optimize IPF Drug Development.
Returning with a revitalized agenda including 25 brand new speakers, the hotly anticipated two-tracked summit is back!
As epithelial targets return to the limelight, innovations in translational models hit their stride and clinical trial competition dramatically heats up; there’s more translational and clinically relevant science for IPF now than ever before, catapulting this archetypal fibrotic disease right to the top of biopharma’s priority list.
Dedicated to providing you with the insights you need to create clinically defining IPF therapeutics, this premier industry forum will unite industry experts from AstraZeneca, Genentech, Ionis, AbbVie, Gilead, Lassen Therapeutics, Pliant, Galecto and more with leading academia, for you to gain back-to-back insights on the science propelling IPF drug development forward.
From dissecting the fibrotic lung microenvironment and comprehensively analyzing multiple translational models alongside bleomycin to including patient-reported outcomes as an endpoint in clinical trials; the 5th IPF Summit is the only end-to-end forum presenting scientific advancements as actionable insights for more innovative and clinically effective drug development.
As organizations across fibrosis, autoimmunity and inflammatory disease turn their heads towards IPF in a bid to capitalize on its strategic opportunity, Join 150+ IPF drug developers this August at this unique forum for a dynamic mix of formal presentations, audience discussions, panel discussions and organized networking and leave with the expertise your team needs to optimize your IPF R&D for 2021 and beyond.
Want to learn more about our brand new 2021 agenda and expert speaker faculty? Click Here